Article

Biosimilars Versus Generics: Differences in the Regulatory Review Process

Conference|ASHP Midyear Clinical Meeting and Exhibition - American Society of Health System Pharmacists Midyear Clinical Meeting and Exhibition

Ashley Mains Espinosa, PharmD, Director of System Pharmacy Business Services at SCL Health, discusses the regulatory review process for biosimilars and how it differs from the generic approval process.

At the American Society for Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition, Ashley Mains Espinosa, PharmD, Director of System Pharmacy Business Services at SCL Health, discussed the regulatory review process for biosimilars and how it differs from the generic review process.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com
Austin Texas | Image credit: Kevin Ruck - stock.adobe.com
Pharmacy Times OPC
Related Content
X-ray image of kidneys with CKD -- Image credit: Crystal light | stock.adobe.com
July 2nd 2025

FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia

Gillian McGovern, Associate Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Destruction of lymphoblasts. Conceptual 3D illustration of treatment of acute lymphoblastic leukemia - Image credit: Dr_Microbe | stock.adobe.com
July 1st 2025

ASCO 2025: Age-Related Differences in Relapsed/Refractory ALL Treatment Outcomes

Kennedy Ferruggia, Assistant Editor
Pharmacy Focus: Oncology Edition – Key Insights and Interviews From the 2024 SABCS Meeting
December 23rd 2024

Pharmacy Focus: Oncology Edition – Key Insights and Interviews From the 2024 SABCS Meeting

Alexandra Gerlach, Associate Editor
ASCO 2025: How AI-Powered Tools Are Reshaping Oncology Data Capture and Clinical Decision-Making
June 30th 2025

ASCO 2025: How AI-Powered Tools Are Reshaping Oncology Data Capture and Clinical Decision-Making

Gayathri Namasivayam, PhD Alana Hippensteele, Lead Editor
FDA Approved Food and Drug Administration concept. Person with FDA icon on virtual screen for Health product standards control system.
June 30th 2025

FDA Approves Emapalumab-Lzsg as First-Ever Treatment for Macrophage Activation Syndrome in Still Disease

Luke Halpern, Assistant Editor